Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events

Back

ESC2024 Premium Access

Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention of cardiovascular events

Session: Lipid-lowering drugs: new insights

Topic: Drug therapy

Speaker: Doctor L. Godoy (Toronto, CA)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Lucas Godoy

Peter Munk Cardiac Centre, Toronto (Canada)

0 follower

7 more presentations in this session

The cardiovascular polypill strategy (acetyl salicylic acid, atorvastatin, ramipril) as baseline treatment after a cardiovascular event supported by compelling evidence: a global expert consensus

Speaker: Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)

Proprotein convertase subtilisin/kexin type 9 levels and the risk of cardiovascular events in statin-treated patients with cardiovascular disease

Speaker: Assistant Professor M. Gohbara (Yokohama, JP)

Safety and Efficacy of Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis

Speaker: Doctor F. Alves Kelly (Sao Paulo, BR)

Efficacy and severity of side-effects of rosuvastatin compared to other statins post-heart-transplantation

Speaker: Ms B. Van Dijk (Rotterdam, NL)

Failure of primary prophylaxis: statin use, risk profile, and outcomes in contemporary patients treated with PCI for first atherosclerotic event

Speaker: Miss H. Anjum (DK)

Access the full session

Lipid-lowering drugs: new insights

Speakers: Doctor L. Godoy, Doctor J. Gonzalez Juanatey, Assistant Professor M. Gohbara, Doctor F. Alves Kelly, Ms B. Van Dijk...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources